WuXi To Lead ‘China First’ Strategy For Lilly’s Novel Cholesterol Drug
This article was originally published in PharmAsia News
Executive Summary
Following the announcement of a strategic partnership last year, WuXi AppTec and Eli Lilly have now finished toxicology studies for the world’s first small molecule drug to target low-density lipoprotein cholesterol and triglycerides, and are aiming for a China-first approval under a global simultaneous development program.